Home > Haematology > ELEVATE-TN: Long-term efficacy in chronic lymphocytic leukemia

ELEVATE-TN: Long-term efficacy in chronic lymphocytic leukemia

Presented By
Dr. John Byrd, Ohio State University College of Medicine, USA
Journal
Physician's Weekly
Conference
ASCO 2021
Trial
Phase 3, ELEVATE-TN
Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in patients with chronic lymphocytic leukaemia (CLL). Results from the 4-year follow-up of the ELEVATE-TN study confirmed previously published interim results. Medicom’s journalist spoke with senior author John Byrd spoke with principle investigator, the D. Warren Brown Chair of Leukemia Research, Dr. John Byrd (Ohio State University College of Medicine, USA). The 4-year follow-up results of the multicentre, open-label, phase 3 ELEVATE-TN study (NCT02475681), which was designed to compare efficacy and safety of acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in patients with treatment-naïve CLL results were presented by Dr. Jeff Sharman (US Oncology Network, USA) at the


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on